Utilizing a range of nanocarriers, including liposomes, polymeric nanoparticles, and gold nanoparticles, these nanotechnology strategies promise enhanced efficacy, greater tolerance, and fewer adverse effects compared to traditional treatment modalities
Ready to Explore Your Options
Archived from the original on 2 June 2014
The Specialist Pharmacy Service (SPS) advises that DPP-4 inhibitors should generally be discontinued when initiating a GLP-1 receptor agonist due to their overlapping mechanisms and limited additional benefit
Jennifer McCauley, a weight management physician at UNC Health, said Medicaid coverage of GLP-1s was incredibly helpful for our patients. Now theyve stopped coverage, so those people are now going back, regaining some of the weight, because theyre unable to obtain these medications, and also are suffering the health consequences of obesity, McCauley told Stateline